Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
29 papers
This review summarizes drug treatments for adult anxiety disorders (panic disorder, generalized anxiety disorder, social anxiety disorder, and specific phobias). It says well-known drugs such as SSRIs and SNRIs are commonly used and approved for some anxiety disorders. The authors found that research into truly new medications is limited, many…
This review summarizes research on promoting mental wellbeing and preventing mental illness. It says many prevention and promotion programs work, including newer digital and community-based approaches, but most strong evidence comes from high-income countries. The review notes big gaps in real-world use, especially in low- and middle-income countries, and calls…
This article proposes a new hypothesis: women report mild-to-moderate depression more often, while men report more severe depression and more suicide. The authors point to possible reasons such as hormone links, men’s tendency to hide feelings or avoid help, and different symptom patterns in men. They say this could mean…
This review explains why the FDA gave Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD. It summarizes six Phase 2 trials (2004–2017) in which MDMA was given in up to three 8-hour sessions combined with preparatory and follow-up therapy, and pooled analyses showed a large effect on PTSD symptoms and…
This review looks at cognitive remediation (CR), which are training methods meant to improve thinking skills in people with psychiatric disorders. It notes that thinking problems are common and hurt daily life. Over the past 50 years the evidence for CR has grown, with the clearest support for treating schizophrenia…
This systematic review searched for clinical trials of psilocybin for substance use problems up to September 2, 2022. The authors found four trials with 151 patients that tested psilocybin combined with psychotherapy for alcohol or tobacco use. These small trials, including one randomized placebo-controlled trial, reported reductions in heavy drinking…
Researchers followed two groups of people who planned to use a psychedelic. They gave questionnaires before the trip, then about two weeks and four weeks after. On average, people reported less avoidance of painful thoughts and feelings, lower depression scores, and less thinking about suicide after using a psychedelic. The…
This paper reviews research on using psychedelic drugs to treat addiction. The authors say scientific and medical interest has grown a lot in the last ten years and that early evidence is starting to show these treatments can be safe and may help with psychiatric problems including addiction. The review…
This article gives health care professionals a plain overview of psilocybin-assisted psychotherapy. It summarizes how psilocybin and its active form psilocin work in the brain, how the body absorbs and clears them, practical issues for dosing and monitoring, legal and access changes, and safety concerns for medically complex patients. The…
This paper describes a pilot study protocol that will test psilocybin-assisted therapy in 20 adult females with anorexia nervosa. Participants will get up to three oral doses (up to 25 mg) over a 6-week period, with psychological preparation, support people involved, and remote follow-up for 12 months. The study aims…
This paper reviews clinical and lab studies about psychedelic therapy, which means using a psychedelic drug together with psychological support. The authors say this approach looks promising for several different mental health problems that share rigid or harmful patterns of feeling, thinking, or acting — especially major depression, depression that…
This study analyzed Global Burden of Disease (GBD) 2021 data from 204 countries to track anxiety disorders in 10–24 year olds from 1990 to 2021. It found a 52% rise in incidence over those 31 years, a sharp increase after 2019, higher rates in females, and rising disability (DALYs) especially…
